283 related articles for article (PubMed ID: 19934396)
1. Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis.
Bliziotis IA; Plessa E; Peppas G; Falagas ME
Ann Pharmacother; 2010 Jan; 44(1):97-106. PubMed ID: 19934396
[TBL] [Abstract][Full Text] [Related]
2. Daptomycin: rationale and role in the management of skin and soft tissue infections.
Seaton RA
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections.
Logman JF; Stephens J; Heeg B; Haider S; Cappelleri J; Nathwani D; Tice A; van Hout BA
Curr Med Res Opin; 2010 Jul; 26(7):1565-78. PubMed ID: 20429820
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
Bounthavong M; Hsu DI
Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
[TBL] [Abstract][Full Text] [Related]
5. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections.
Kern WV
Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659
[TBL] [Abstract][Full Text] [Related]
6. Management of cSSTIs: the role of daptomycin.
Garau J
Curr Med Res Opin; 2006 Nov; 22(11):2079-87. PubMed ID: 17076967
[TBL] [Abstract][Full Text] [Related]
7. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials.
Beibei L; Yun C; Mengli C; Nan B; Xuhong Y; Rui W
Int J Antimicrob Agents; 2010 Jan; 35(1):3-12. PubMed ID: 19900794
[TBL] [Abstract][Full Text] [Related]
8. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections].
Mathiesen L; Midtvedt T; Solberg CO
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2383-4. PubMed ID: 16998552
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study.
Gonzalez-Ruiz A; Beiras-Fernandez A; Lehmkuhl H; Dohmen PM; Loeffler J; Chaves RL
Int J Antimicrob Agents; 2013 Apr; 41(4):372-8. PubMed ID: 23499225
[TBL] [Abstract][Full Text] [Related]
10. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin.
Owens RC; Lamp KC; Friedrich LV; Russo R
Am J Med; 2007 Oct; 120(10 Suppl 1):S6-12. PubMed ID: 17904950
[TBL] [Abstract][Full Text] [Related]
11. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
[TBL] [Abstract][Full Text] [Related]
12. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
Davis SL; McKinnon PS; Hall LM; Delgado G; Rose W; Wilson RF; Rybak MJ
Pharmacotherapy; 2007 Dec; 27(12):1611-8. PubMed ID: 18041881
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
[TBL] [Abstract][Full Text] [Related]
14. Future directions with daptomycin.
Livermore DM
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii41-iii49. PubMed ID: 18829725
[TBL] [Abstract][Full Text] [Related]
15. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria.
Katz DE; Lindfield KC; Steenbergen JN; Benziger DP; Blackerby KJ; Knapp AG; Martone WJ
Int J Clin Pract; 2008 Sep; 62(9):1455-64. PubMed ID: 18662172
[TBL] [Abstract][Full Text] [Related]
17. Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials.
Kyriakidou KG; Rafailidis P; Matthaiou DK; Athanasiou S; Falagas ME
Clin Ther; 2008 Oct; 30(10):1859-68. PubMed ID: 19014841
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
Arbeit RD; Maki D; Tally FP; Campanaro E; Eisenstein BI;
Clin Infect Dis; 2004 Jun; 38(12):1673-81. PubMed ID: 15227611
[TBL] [Abstract][Full Text] [Related]
19. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections.
Lipsky BA; Stoutenburgh U
J Antimicrob Chemother; 2005 Feb; 55(2):240-5. PubMed ID: 15659542
[TBL] [Abstract][Full Text] [Related]
20. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus.
Elliott DJ; Zaoutis TE; Troxel AB; Loh A; Keren R
Pediatrics; 2009 Jun; 123(6):e959-66. PubMed ID: 19470525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
